Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. (Q54079258)

24 May 2018

title

Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. (English)

1 reference

24 May 2018

0 references

Kawai T

1

1 reference

24 May 2018

Takei I

2

1 reference

24 May 2018

Oguma Y

3

1 reference

24 May 2018

Ohashi N

4

1 reference

24 May 2018

Tokui M

5

1 reference

24 May 2018

Oguchi S

6

1 reference

24 May 2018

Katsukawa F

7

1 reference

24 May 2018

Hirose H

8

1 reference

24 May 2018

Shimada A

9

1 reference

24 May 2018

Watanabe K

10

1 reference

24 May 2018

Saruta T

11

1 reference

24 May 2018

publication date

1 September 1999

1 reference

24 May 2018

number of pages

6

1 reference

based on heuristic

inferred from page(s)

published in

Metabolism

1 reference

24 May 2018

volume

48

1 reference

24 May 2018

issue

9

1 reference

24 May 2018

page(s)

1102-1107

1 reference

24 May 2018

Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

Health consequences of fat distribution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

Importance of intra-abdominal visceral fat accumulation to coronary atherosclerosis in heterozygous familial hypercholesterolaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

Pioglitazone promotes insulin-induced activation of phosphoinositide 3-kinase in 3T3-L1 adipocytes by inhibiting a negative control mechanism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

Serum leptin level: possible association with haematopoiesis in adolescents, independent of body mass index and serum insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

Antihypertensive effects of CS-045 treatment in obese Zucker rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

Mental distress, obesity and body fat distribution in middle-aged men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose-response study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

Endocrine and metabolic aberrations in men with abdominal obesity in relation to anxio-depressive infirmity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

The interactions between hypothalamic-pituitary-adrenal axis activity, testosterone, insulin-like growth factor I and abdominal obesity with metabolism and blood pressure in men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

Glucocorticoid receptor messenger ribonucleic acid in different regions of human adipose tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

Regional differences in the control of lipolysis in human adipose tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

Metabolism of adipose tissue in intraabdominal depots of nonobese men and women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

The morphology and metabolism of intraabdominal adipose tissue in men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

Differences in lipolysis between human subcutaneous and omental adipose tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

Troglitazone action is independent of adipose tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2899%2990122-1

10.1016/S0026-0495(99)90122-1

7 January 2021

Identifiers

DOI

1 reference

24 May 2018

PubMed ID

10484048

1 reference

24 May 2018